Literature DB >> 15885082

Atopic dermatitis-like pruritic skin inflammation caused by feeding a special diet to HR-1 hairless mice.

Masanori Fujii1, Junko Tomozawa, Nobuaki Mizutani, Takeshi Nabe, Kiichiro Danno, Shigekatsu Kohno.   

Abstract

Dry skin/barrier dysfunction is considered to be one of the characteristic features of atopic dermatitis (AD). When HR-1 hairless mice are fed a special diet, HR-AD, dry red skin is induced. We examined whether HR-AD-fed mouse could be used as a model for AD by showing itch-associated scratching behaviour and by analysing the immunological change. HR-1 mice were fed HR-AD from 4 weeks old. HR-AD-fed mice showed severe dry skin symptoms accompanied by a decrease in dermal water content and an increase in transepidermal water loss and prolonged scratching bout duration on day 14 or 28. These symptoms became gradually worse until day 56. Marked epidermal hyperplasia and slight increase in CD4+ cells in the skin were observed from day 28. In contrast, increases in circulating T cells and serum immunoglobulin E were seen from day 41. Other skin-infiltrating inflammatory cells, such as eosinophils and mast cells, were increased on day 56 but not on day 28. Though daily oral treatment with dexamethasone reduced the increased numbers of these cells, it did not affect the dry skin symptoms or the prolonged scratching episodes. In contrast, the development of dry skin was inhibited by feeding with 10% normal diet-containing HR-AD. The skin barrier dysfunction in HR-AD-fed mice is closely associated with the development of AD-like pruritus. Changes in the immunological parameters observed may be the consequence of skin barrier dysfunction. Our findings suggest that HR-AD-fed mouse could be used as a dry skin-based experimental model for AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885082     DOI: 10.1111/j.0906-6705.2005.00313.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  8 in total

1.  Extracellularly Extruded Syntaxin-4 Is a Potent Cornification Regulator of Epidermal Keratinocytes.

Authors:  Nanako Kadono; Natsumi Hagiwara; Takashi Tagawa; Kenji Maekubo; Yohei Hirai
Journal:  Mol Med       Date:  2015-01-14       Impact factor: 6.354

Review 2.  Mast cells in atopic dermatitis.

Authors:  Toshiaki Kawakami; Tomoaki Ando; Miho Kimura; Bridget S Wilson; Yuko Kawakami
Journal:  Curr Opin Immunol       Date:  2009-10-14       Impact factor: 7.486

3.  Inhibitory Effect of Polyphenol-Rich Fraction from the Bark of Acacia mearnsii on Itching Associated with Allergic Dermatitis.

Authors:  Nobutomo Ikarashi; Wataru Sato; Takahiro Toda; Makoto Ishii; Wataru Ochiai; Kiyoshi Sugiyama
Journal:  Evid Based Complement Alternat Med       Date:  2012-01-22       Impact factor: 2.629

4.  Brain allopregnanolone induces marked scratching behaviour in diet-induced atopic dermatitis mouse model.

Authors:  Masanori Fujii; Sayaka Ohgami; Erika Asano; Takanori Nakayama; Takahiro Toda; Takeshi Nabe; Susumu Ohya
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

5.  Influence of Oral Administration of Lactic Acid Bacteria Metabolites on Skin Barrier Function and Water Content in a Murine Model of Atopic Dermatitis.

Authors:  Yoshihiro Tokudome
Journal:  Nutrients       Date:  2018-12-01       Impact factor: 5.717

Review 6.  Meibomian Gland Dysfunction: What Have Animal Models Taught Us?

Authors:  Mingxia Sun; Isabel Y Moreno; Michelle Dang; Vivien J Coulson-Thomas
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

Review 7.  Mechanisms and Management of Itch in Dry Skin.

Authors:  Catharina Sagita Moniaga; Mitsutoshi Tominaga; Kenji Takamori
Journal:  Acta Derm Venereol       Date:  2020-01-15       Impact factor: 3.875

8.  Dietary ceramide 2-aminoethylphosphonate, a marine sphingophosphonolipid, improves skin barrier function in hairless mice.

Authors:  Nami Tomonaga; Yuki Manabe; Kazuhiko Aida; Tatsuya Sugawara
Journal:  Sci Rep       Date:  2020-08-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.